Tim O'Rourke Takes Over as CEO of Agilon Health Inc., Succeeding Ronald A. Williams, Who Remains Chairman
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Source: moomoo
Leadership Change: A.G.I.L.O.N Health has appointed Tim O'Rourke as the new CEO, succeeding Ronald A. Williams.
Continuity in Governance: Ronald A. Williams will remain with the company as Chairman, ensuring continuity in leadership.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGL
Wall Street analysts forecast AGL stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 90.370
Low
0.88
Averages
0.88
High
0.88
Current: 90.370
Low
0.88
Averages
0.88
High
0.88
About AGL
agilon health, inc. is a healthcare company. The Company operates a Medicare-centric, capitated line of business. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing monthly payments to manage the total healthcare needs of its physician partners attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform supports the transition to a Total Care Model with technology, people, process and capital.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Far-Right One Nation Party Secures First-Ever Seat in Australia
- Historic Victory: The far-right One Nation party secured its first-ever seat in the lower house during the Farrer by-election, with candidate David Farley capturing nearly 60% of the vote, marking a significant milestone and highlighting a deepening crisis for the traditional center-right Liberal-National coalition.
- Political Turning Point: In his victory speech, Farley emphasized nationalist themes and environmental policies, vowing to target 'damn net-zero programs' and criticizing immigration levels, indicating a shift towards more conservative policy directions that could influence future governance.
- Election Impact: Treasurer Jim Chalmers described the outcome as a 'bloodbath for the Coalition,' noting that it suggests the Liberals and Nationals will find it nearly impossible to govern without One Nation, reflecting the increasing challenges the opposition faces in building a cohesive national platform.
- Economic Pressure: With national debt nearing A$1 trillion and inflation driven by global energy shocks, the government is under pressure to address voter dissatisfaction in the upcoming 2026-27 Federal Budget, specifically targeting the housing market and tax system to alleviate economic frustrations among voters.
See More
Agilon Health Q1 Earnings Beat Expectations, Raises 2026 Outlook
- Earnings Beat: Agilon Health's Q1 earnings exceeded market expectations, showcasing the company's strong performance in the healthcare sector, which significantly boosted its stock price and reflected investor confidence in future growth.
- Raised 2026 Outlook: The company raised its financial outlook for 2026, indicating management's optimistic view on future business growth, which is likely to attract more investor interest and enhance market confidence.
- Improved Medical Margins: Although membership numbers declined, the improvement in medical margins effectively offset this impact, demonstrating the company's success in cost control and service efficiency, thereby strengthening its competitive position in the market.
- Positive Market Reaction: The stock price surged due to the earnings beat and raised outlook, reflecting market recognition of Agilon Health's ongoing growth potential in the healthcare industry, which may attract more institutional investor attention.
See More
Latest Wall Street Ratings and Outlook
- Goldman Sachs Reiterates Nvidia Buy: Goldman Sachs anticipates a 'beat and raise' quarter for Nvidia ahead of its earnings report this month, focusing on the potential upside to its $1 trillion datacenter guidance, which could positively impact stock performance.
- JPMorgan Upgrades Freshpet: JPMorgan upgraded Freshpet from hold to buy following a first-quarter sales beat and guidance increase, expecting a rebound in share price as investors buy the dip after a 9% decline.
- Barclays Reiterates Microsoft Overweight: Barclays noted that Microsoft's story remains strong post-investor meetings, emphasizing management's focus on efficiency gains that are likely to enhance Azure growth and competitive positioning.
- Jefferies Upgrades Agilon Health: Jefferies highlighted improving visibility for Agilon Health, with supportive Medicare Advantage rates locked in, suggesting a favorable outlook that could attract investor interest moving forward.
See More
Agilon Health Q1 Revenue Surpasses Expectations, Raises FY2026 Guidance
- Q1 Earnings Beat: Agilon Health reported first-quarter revenue of $1.42 billion, exceeding Wall Street's expectations of $1.38 billion, which underscores the company's robust market performance and growth potential, thereby boosting investor confidence.
- FY2026 Guidance Raised: The company raised its FY2026 revenue guidance to between $5.68 billion and $5.81 billion, up from the previous forecast of $5.41 billion to $5.58 billion, reflecting an optimistic outlook for future performance.
- Analyst Upgrades: Jefferies upgraded Agilon's stock rating from 'Hold' to 'Buy' while increasing the price target by 75% to $48, indicating strong analyst confidence in the company's growth trajectory.
- Bullish Market Sentiment: AGL shares surged over 50% in pre-market trading, with retail investor sentiment on Stocktwits flipping to 'bullish', demonstrating positive market expectations for the company's future.
See More
agilon health Exceeds Q1 2026 Earnings Expectations
- Financial Performance Boost: agilon health reported approximately $1.42 billion in revenue for Q1 2026, although down from $1.53 billion in Q1 2025, it exceeded expectations, demonstrating effective strategies in medical cost management and risk adjustment.
- Leadership Transition: New CEO Tim O'Rourke will take office on May 7, with management emphasizing that this change will enhance execution and strategic direction, thereby boosting market confidence.
- Increased Membership Data Transparency: The company now has risk scores on approximately 85% of its members, which enhances forecasting capabilities, although it maintains a conservative net cost trend outlook of about 7% for 2026.
- Clinical Pathway Expansion: The congestive heart failure program is deployed across 90% of markets, with first diagnosis inpatient rates improving from 25% to less than 5%, and the company plans to rapidly scale COPD and broader lung health pathways through 2026, further enhancing clinical outcomes and competitive positioning.
See More
AGILON HEALTH STOCK FALLS 8.1% FOLLOWING JP MORGAN'S DOWNGRADE TO UNDERWEIGHT FROM NEUTRAL
- AGILON Health Shares Decline: Agilon Health's shares fell by 8.1% following a significant downgrade from JP Morgan.
- JP Morgan's Analysis: The downgrade was attributed to concerns regarding Agilon Health's performance and market position, leading to a reassessment of its value.
See More
Far-Right One Nation Party Secures First-Ever Seat in Australia
- Historic Victory: The far-right One Nation party secured its first-ever seat in the lower house during the Farrer by-election, with candidate David Farley capturing nearly 60% of the vote, marking a significant milestone and highlighting a deepening crisis for the traditional center-right Liberal-National coalition.
- Political Turning Point: In his victory speech, Farley emphasized nationalist themes and environmental policies, vowing to target 'damn net-zero programs' and criticizing immigration levels, indicating a shift towards more conservative policy directions that could influence future governance.
- Election Impact: Treasurer Jim Chalmers described the outcome as a 'bloodbath for the Coalition,' noting that it suggests the Liberals and Nationals will find it nearly impossible to govern without One Nation, reflecting the increasing challenges the opposition faces in building a cohesive national platform.
- Economic Pressure: With national debt nearing A$1 trillion and inflation driven by global energy shocks, the government is under pressure to address voter dissatisfaction in the upcoming 2026-27 Federal Budget, specifically targeting the housing market and tax system to alleviate economic frustrations among voters.
See More
Agilon Health Q1 Earnings Beat Expectations, Raises 2026 Outlook
- Earnings Beat: Agilon Health's Q1 earnings exceeded market expectations, showcasing the company's strong performance in the healthcare sector, which significantly boosted its stock price and reflected investor confidence in future growth.
- Raised 2026 Outlook: The company raised its financial outlook for 2026, indicating management's optimistic view on future business growth, which is likely to attract more investor interest and enhance market confidence.
- Improved Medical Margins: Although membership numbers declined, the improvement in medical margins effectively offset this impact, demonstrating the company's success in cost control and service efficiency, thereby strengthening its competitive position in the market.
- Positive Market Reaction: The stock price surged due to the earnings beat and raised outlook, reflecting market recognition of Agilon Health's ongoing growth potential in the healthcare industry, which may attract more institutional investor attention.
See More
Latest Wall Street Ratings and Outlook
- Goldman Sachs Reiterates Nvidia Buy: Goldman Sachs anticipates a 'beat and raise' quarter for Nvidia ahead of its earnings report this month, focusing on the potential upside to its $1 trillion datacenter guidance, which could positively impact stock performance.
- JPMorgan Upgrades Freshpet: JPMorgan upgraded Freshpet from hold to buy following a first-quarter sales beat and guidance increase, expecting a rebound in share price as investors buy the dip after a 9% decline.
- Barclays Reiterates Microsoft Overweight: Barclays noted that Microsoft's story remains strong post-investor meetings, emphasizing management's focus on efficiency gains that are likely to enhance Azure growth and competitive positioning.
- Jefferies Upgrades Agilon Health: Jefferies highlighted improving visibility for Agilon Health, with supportive Medicare Advantage rates locked in, suggesting a favorable outlook that could attract investor interest moving forward.
See More
Agilon Health Q1 Revenue Surpasses Expectations, Raises FY2026 Guidance
- Q1 Earnings Beat: Agilon Health reported first-quarter revenue of $1.42 billion, exceeding Wall Street's expectations of $1.38 billion, which underscores the company's robust market performance and growth potential, thereby boosting investor confidence.
- FY2026 Guidance Raised: The company raised its FY2026 revenue guidance to between $5.68 billion and $5.81 billion, up from the previous forecast of $5.41 billion to $5.58 billion, reflecting an optimistic outlook for future performance.
- Analyst Upgrades: Jefferies upgraded Agilon's stock rating from 'Hold' to 'Buy' while increasing the price target by 75% to $48, indicating strong analyst confidence in the company's growth trajectory.
- Bullish Market Sentiment: AGL shares surged over 50% in pre-market trading, with retail investor sentiment on Stocktwits flipping to 'bullish', demonstrating positive market expectations for the company's future.
See More
agilon health Exceeds Q1 2026 Earnings Expectations
- Financial Performance Boost: agilon health reported approximately $1.42 billion in revenue for Q1 2026, although down from $1.53 billion in Q1 2025, it exceeded expectations, demonstrating effective strategies in medical cost management and risk adjustment.
- Leadership Transition: New CEO Tim O'Rourke will take office on May 7, with management emphasizing that this change will enhance execution and strategic direction, thereby boosting market confidence.
- Increased Membership Data Transparency: The company now has risk scores on approximately 85% of its members, which enhances forecasting capabilities, although it maintains a conservative net cost trend outlook of about 7% for 2026.
- Clinical Pathway Expansion: The congestive heart failure program is deployed across 90% of markets, with first diagnosis inpatient rates improving from 25% to less than 5%, and the company plans to rapidly scale COPD and broader lung health pathways through 2026, further enhancing clinical outcomes and competitive positioning.
See More
AGILON HEALTH STOCK FALLS 8.1% FOLLOWING JP MORGAN'S DOWNGRADE TO UNDERWEIGHT FROM NEUTRAL
- AGILON Health Shares Decline: Agilon Health's shares fell by 8.1% following a significant downgrade from JP Morgan.
- JP Morgan's Analysis: The downgrade was attributed to concerns regarding Agilon Health's performance and market position, leading to a reassessment of its value.
See More
